Zobrazeno 1 - 10
of 29
pro vyhledávání: '"V V Kaliuzhin"'
Autor:
V V Kaliuzhin, O F Sibireva, I D Bespalova, E V Kaliuzhina, L M Tkalich, T A Milovanova, I A Osikhov, B Iu Murashev
Publikováno v:
Терапевтический архив, Vol 85, Iss 10, Pp 29-33 (2013)
AIM: To comprehensively study hemostasis pathology and its association with the laboratory markers and mediators of inflammation in patients with metabolic syndrome (MS)/MATERIAL AND METHODS: One hundred and eleven patients with type 2 diabetes melli
Externí odkaz:
https://doaj.org/article/095aad7661734e939d06d876be5ff988
Autor:
V V Kaliuzhin, O F Sibireva, O I Urazova, L M Tkalich, L I Zibnitskaia, E V Kaliuzhina, É A Sazonov, V Iu Grankina
Publikováno v:
Терапевтический архив, Vol 85, Iss 9, Pp 77-81 (2013)
Aim. To study the effect of eprosartan, an angiotensin II type 1 (AT1) receptor blocker, with sympatholytic activity on the hemostatic system in patients with chronic kidney disease (CKD) associated with hereditary thrombophilia. Subjects and methods
Externí odkaz:
https://doaj.org/article/73a10f17077f4af9ac1c7272fe33b016
Publikováno v:
Терапевтический архив, Vol 85, Iss 5, Pp 68-72 (2013)
AIM: To comparatively estimate the time course of changes in key metabolic parameters and quality of life (QL) in patients with coronary heart disease during 4-week therapy with atenolol and amlodipine/MATERIAL AND METHODS: The 4-week randomized open
Externí odkaz:
https://doaj.org/article/8256ffd08f894f308e4c2473b2370048
Publikováno v:
Терапевтический архив, Vol 84, Iss 12, Pp 18-22 (2012)
AIM: To identify the factors most substantially influencing the quality of life (QL) in patients with coronary heart disease (CHD) associated with metabolic syndrome (MS), by using the principal component method. /MATERIAL AND METHODS: One hundred an
Externí odkaz:
https://doaj.org/article/061c9b3cb97f45fbb17e70be39c0e535
Autor:
I D, Bespalova, V V, Kaliuzhin, N V, Riazantseva, Iu A, Mediantsev, I A, Osikhov, B Iu, Murashev
Publikováno v:
Klinicheskaia meditsina. 91(12)
To study pleiotropic effects of atorvastatin during 8-week therapy of metabolic syndrome and estimate their relationship with dynamics of quality of life characteristics (QLC).This 8-week study included 36 patients with stage II hypertensive disease
Autor:
V V, Kaliuzhin, O F, Sibireva, I D, Bespalova, E V, Kaliuzhina, L M, Tkalich, T A, Milovanova, I A, Osikhov, B Iu, Murashev
Publikováno v:
Terapevticheskii arkhiv. 85(10)
To comprehensively study hemostasis pathology and its association with the laboratory markers and mediators of inflammation in patients with metabolic syndrome (MS).One hundred and eleven patients with type 2 diabetes mellitus, who were diagnosed as
Autor:
A E, Tepliakov, E Iu, Pushnikova, V V, Kaliuzhin, I D, Bespalova, E V, Kaliuzhina, M I, Kaliuzhina
Publikováno v:
Klinicheskaia meditsina. 91(4)
This three-week open uncontrolled study included 34 men (mean age 53.14+-1.19 yr) with coronary heart disease (CHD) and insulin resistance (HOMA2. 77); it was designed to estimate effect of amlodipine on transcapillary oxygen metabolism (TCOM). Multi
Autor:
V V, Kaliuzhin, A T, Tepliakov, N V, Riazantseva, I D, Bespalova, D Iu, Kamaev, E V, Kaliuzhina
Publikováno v:
Terapevticheskii arkhiv. 84(12)
To identify the factors most substantially influencing the quality of life (QL) in patients with coronary heart disease (CHD) associated with metabolic syndrome (MS), by using the principal component method.One hundred and two male patients (mean age
Publikováno v:
Klinicheskaia laboratornaia diagnostika. (8)
The article deals with studying the degree of increase of the von Willebrand factor and the concentration of endothelin-1 in blood plasma in the subgroups of patients with diabetes mellitus formed depending on of type of disease and presence of pheno
Publikováno v:
Terapevticheskii arkhiv. 82(6)
to study the activity of free radical processes in patients with alcoholism and renal lesion (A+RL) and the implication of depressed efficiency of the regulatory mechanisms limiting the accumulation of highly toxic products of lipid free radical oxid